Philadelphia Business Journal by John George, Senior Reporter
Aclaris Therapeutics raised $20.9 million in private stock sale this week, according to documents filed with the Securities and Exchange Commission.
The biopharmaceutical company, based in Malvern, Pa., is specializing in developing new treatments for skin disorders.
Philadelphia law firm Duane Morris served as financial adviser to Aclaris for the company’s series A venture capital financing. The identity of the investors was not disclosed.
Aclaris, established earlier this year, is led by President and CEO Neal Walker who was previously the chief executive of another local biopharmaceutical company, Vicept, which was acquired by Allergan last year in a deal valued at up to $275 million.
